The FDA issued a warning letter to Harbin Jixianglong Biotech after inspections found the company allegedly attempted to bypass recently introduced GLP-1 receptor agonist import safeguards for semaglutide APIs. FDA said Jixianglong was on its “green list,” but investigators found it reportedly bought semaglutide from an external site not on the list and then relabeled and repackaged batches for shipment. According to the agency, inspectors documented missing documentation and batch-record controls tied to repackaging and labeling, and the company initially did not fully address the regulator’s concerns about batches already in the U.S. market. The warning follows FDA’s September 2025 effort to restrict GLP-1 API imports from unverified foreign sources. The FDA’s action underscores how quickly manufacturing documentation and supplier verification requirements are becoming decisive in GLP-1 commercialization, particularly as demand continues to drive fast-moving API procurement and logistics.